Pfizer provides update on U.S. FDA review of Abrocitinib and XELJANZ filings

Pharma News update

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for XELJANZ/XELJANZ XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis. The FDA cited its ongoing review of Pfizer's post-marketing safety study, ORAL Surveillance, evaluating tofacitinib in rheumatoid arthritis patients, as a factor for the extensions.

“We remain confident in the benefit-risk profiles of abrocitinib and XELJANZ, both of which have been demonstrated in robust clinical trial programs,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

“For people who are suffering with moderate to severe atopic dermatitis or active ankylosing spondylitis, many have limited treatment options. We look forward to hearing from the FDA as we work to bring these important potential treatment options to the appropriate patients.”

As communicated on April 7, 2021, the FDA had previously extended the PDUFA goal dates to early Q3 2021. ​

Tags : #Pfizer #FDA #Abrocitinib #Xeijanz #FDANews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Advancing Healthcare Access: ScreenHer initiative in Pakistan close to reaching milestone of 20,000 diabetes screenings in 70 clinics February 26, 2024
FICCI Ladies Organization organized an interaction with one of the doyens of Indian IT industry Dr BVR Mohan ReddyFebruary 26, 2024
Former Secretary General of SCSC, Krishna Yedula conferred with Doctorate in HumanityFebruary 25, 2024
Project Champion School Games held February 25, 2024
Daksha 3.0, a nation level techno-test organised by Anurag University concludedFebruary 25, 2024
Mechanisation of Visakhapatnam Port is almost completeFebruary 24, 2024
Recovery Process After Contoura Surgery: Tips and Insights from an ExpertFebruary 24, 2024
Understanding Age-Related Macular Degeneration (AMD) and the Role of NutritionFebruary 24, 2024
Impact of Alcohol Consumption on Eye Health: Insights from a Senior Cataract SurgeonFebruary 23, 2024
Better health of healthcare workers in India : A Closer Look” Insights by Dr. Gopal Sharan MD & CEO of TRLS Healthcare ConsultancyFebruary 23, 2024
Chandrayaan Soft landing of India sent a strong message to the world not to take Indians light: Dr Prakash Chauhan, Director National Remote Sensing CenterFebruary 23, 2024
Dr Raj Nagarkar Leads Master Class On Robotic Surgery For Postgraduates At MASICON 2024 In NashikFebruary 23, 2024
Nanhaagyan Foundation Illuminates Pune with the Resplendent Healing Light Awards 2024February 23, 2024
Anifest India 2024: Pioneering Creativity in Pune's Animation Landscape"February 23, 2024
A Tie with a difference, promoting a cause, 17 SDGs of UNFebruary 22, 2024
Worldwide EndoMarch, Endo Run to raise mass awareness on Endometriosis!February 21, 2024
Uptick In Respiratory, and Cardiac Problems Due To Poor Air Quality In DelhiFebruary 21, 2024
Evidence shows risks associated with energy drinks in childrenFebruary 21, 2024
iHub-Data at IT-Hyderabad announces collaborative initiative with technical institutions for AI/ML training programsFebruary 20, 2024
Viatris Receives Global Minimized Risk of Antimicrobial Resistance Certification, Advancing its Commitment to Responsible Antibiotic ProductionFebruary 20, 2024